AXIS Consulting is the leading provider of strategic market access and health technology assessments in Ireland with over 100 completed submissions to the Irish authorities and with significant success with reimbursement applications. We are well known internationally for our expertise and knowledge on the Irish reimbursement pathway in particular whilst we also support companies with submissions to the SMC/ Scotland and BeNeLuxA. Our client base is diverse, encompassing the public and private healthcare sectors and includes many pharmaceutical & medical technology companies in Ireland & the UK. The AXIS Consulting team includes highly experienced health economists, researchers, statisticians and analysts providing a complete range of market access services for our clients.
External link for AXIS Healthcare Consulting Ltd
19-22 Lower Baggot Street
Dublin 2, Dublin D02 X658, IE
12 Galway Technology Centre
Wellpark Road
Galway, Galway H91C9P5, IE
Following on from the great response to our post during the week on our 'ask us anything' Free Virtual Information Session, (which is booking up quickly, so don't miss out 😉), we would like your feedback on what topics you would be most interested in hearing about, check out the options below and let us know! #poll #haveyoursay #AXISUK
This content isn’t available here
Access this content and more in the LinkedIn app
💡 To celebrate our recent expansion into the UK, AXIS are excited to announce we will be offering a series of FREE webinars, plus one-on-one advisory clinics, over the coming months. We will be starting with an ‘ask us anything session’ in June where you can come online with us and, well… ask us anything! Whether it’s general advice on navigating the UK market, or advice on a specific HTA problem, we’ll be happy to help. Just get in touch (details below) and book in a free and confidential 20 minutes with the team. ⚠ These places are strictly limited and are first-come-first-served, so don’t miss out! We’ve held 2 Wednesdays in June, Wed 12th and Wed 19th, where you can book in a 20 minutes between the hours of 10am and 4pm. To book your free slot please use this link https://shorturl.at/oNQWY If these times don’t work, contact Carl Prescott at carl@axisconsultinguk.com and we will consider if there is any other availability. #onetoonesession #booknow #ukmarketquestions #ukmarketaccess #hta #NICE #SMC
📢 Masterclass Announcement!!!! Brenda Dooley, AXIS CEO and AXIS Head of HTA Consulting, UK, Carl Prescott will take part in the Life Science Access Academy's upcoming Masterclass ‘The Use of AI Tools in a NICE Submission – Reality or Pipedream?’ 📅 Tuesday 14th May 2024 13:00 - 14:00 (BST). This exciting 60-minute masterclass for LSAA members will look at the opportunities for using AI in HTA and reflect on what can be done to overcome the barriers. Artificial intelligence offers transformative opportunities for the way health technology assessment (HTA) is conducted. Many of the benefits, such as increased speed and accuracy of data analysis, are easy to envision, however, there are many barriers when it comes to embedding AI into routine HTA practice. Key Learning Objectives: 💡 Gain an understanding of the potential opportunities for AI in HTA, particularly for HTA bodies and for the Life Science industry. 💡 Learn about the potential barriers to embedding AI in HTA. 💡 Find out what can be done to try to overcome these barriers. For more information or to book your place please contact The Life Science Access Academy at this link https://lnkd.in/ed63pWVZ #masterclass #AI #AIinHTA #HTA #MarketAccess #thoughtleaders
Brenda Dooley and Carl Prescott are attending the #ABPIconf24 today in London. If you are in attendance be sure to catch up with them 🫱🏻🫲🏼
Head of HTA Consulting UK at AXIS Healthcare Consulting. Former Senior Technical Adviser (Methods) at NICE - National Institute for Health and Care Excellence
Brenda Dooley and I from AXIS Healthcare Consulting Ltd are at at the #ABPIconf24 today, come and say hello if you're around! First session, on the O'Shaughnessy review, is really interesting, focusing on the need for everyone to collaborate to improve the number of trials in the UK. This can be helped by engaging early with partners like the regulator and HTA bodies. Also touched on the importance of meaningful representation within trials so that they are more inclusive.
Really looking forward to this afternoon's panel discussion 'Payers & Providers: The Value of Partnership - Striking a balance between the values of innovation, affordability & continuity of supply at The Pharmaceutical Managers Institute Pharma Summit #discussion #payers #pharma #patientgroups #agency #thepmi24
AXIS are all set for the The Pharmaceutical Managers Institute Pharma Summit at Croke Park. As platinum sponsors we are delighted to support this event. Brenda Dooley, Allister Upton, Carl Prescott, Laura Rouncivell and Caroline McNeill are in attendance and looking forward to the day. #pharmasummit #pmi #marketaccess #hta #irishandukbusiness
AXIS Consulting are thrilled to feature in the latest edition of the Business Post’s ‘Making It Work’, highlighting our journey of growth and commitment to excellence in pharmaceutical consulting. As a boutique consultancy, AXIS specialises in providing tailored submissions to healthcare authorities in Ireland and the UK, including, the NCPE, NICE and SMC. We strive to secure timely approvals for important and effective new medicines that will benefit patients. We firmly believe that by working together, the pharmaceutical companies and the authorities, can improve the current timelines to reimbursement. We are grateful for the opportunity for Brenda Dooley, CEO of AXIS to be featured in this insightful article, it fuels our passion to continue providing unparalleled support to our clients and making a real difference in the healthcare industry. It also provided an opportunity to highlight the support of Enterprise Ireland on our journey of growth, who have been instrumental in fostering connections and providing resources beyond financial assistance. 💡 Want to be part of a dynamic and diverse team dedicated to driving positive change in healthcare? Stay tuned for exciting opportunities as we expand our workforce. #newsarticle #inthenews #marketaccess #businessgrowth #businessexpansion #irishandukbusiness #patientaccess #hta #nichebusiness https://bit.ly/49F7Gi7
🔸 Only 2 week to go! 🔸 AXIS Consulting are once again proud to be the Platinum sponsor of The Pharmaceutical Managers Institute (PMI) Pharma Summit which takes place on Thursday, 18th of April 2024 in the Croke Park Convention Centre, Dublin. 🗣 The theme of the Pharma Summit this year is “Exploring the Diverse Value of Irish Healthcare” and will involve many keynote speakers and a panel discussion chaired by AXIS Founder and CEO, Brenda Dooley and featuring significant contributions from AXIS Head of HTA Consulting, UK, Carl Prescott - The discussion is entitled “Payers & Providers: The Value of Partnership – Striking a balance between the values of innovation, affordability & continuity of supply” and Carl will be joined by Duggan Caitriona, Country Manager – Amgen & Chair of Market Access Advisory Forum – IPHA, Deirdre Kelly, Country Manager – Consilient Health & Vice Chair – Medicines for Ireland and Angela Clayton-Lea, Acting CEO – Clinical Trials Ireland. Additionally, the AXIS team, Allister Upton, Head of HTA, Ireland, Laura Rouncivell, HTA Value & Strategy Lead, Ireland and Caroline McNeill, Business Operations Lead, will be delighted to connect with those in attendance on the day, so be sure and drop by the AXIS stand. #pharmasummit #thepmi #pmisummit2024 #platinumsponsor #sponsor #exhibitor #marketaccess #patientcare #only2weeks2go
With just a few days left to provide your input on including NICE technology appraisal recommendations in clinical guideline topic areas make sure you have your say! The consultation seeks to gather diverse perspectives on these changes to ensure a comprehensive understanding of potential implications. For insights on navigating these changes and support in developing HTA submissions to NICE connect with AXIS Head of HTA Consulting, UK, Carl Prescott or email carl@axisconsultinguk.com. Stay informed and be part of the conversation driving progress in healthcare access and decision making. #MarketAccess #NICEConsultation #healthcareinnovation #patientcare
Yesterday Carl Prescott & Anne-Marie Barnes attended the OHE Webinar ‘The Future of NICE in a Changing HTA Landscape’, in recognition of NICE’s upcoming 25th birthday & took away some really valuable insights: 1️⃣ The trajectory of HTA & the challenges ◾ Since the publication of the RWE framework, NICE has seen improvement with the quality of RWE & type of analyses used in appraisals which is really helping NICE to be in a better position to make decisions where good quality evidence is lacking. ◾ There are still challenges in how NICE deal with uncertainty in evidence or in a situation where the evidence doesn’t exist, including how this uncertainty is factored into decision making and balanced with other considerations. ◾ NICE are pleased to see the severity modifier is being used within non-oncology appraisals but overall, there are a lower number of appraisals than NICE anticipated utilising the modifier. ◾ The trend for increased number of annual appraisals is set to continue with NICE keen to consider proportionate approaches for low-risk appraisals or where the value is clear for a new treatment, this is an area which is being actively worked on – so watch this space! 2️⃣ Digital health advancements ◾ How do we create stronger alignment between NICE, MHRA, & the NHS to increase access of digital health technologies to patients? ◾ Digital technologies can improve so fast that version 2.0 could be ready before the assessment of v1.0 has even been finalised. ◾ There will be significant challenges in HTA as digital health technologies evolve utilising AI & Machine Learning – there is a need for much greater collaboration between Regulatory / Companies/ Health care systems & NICE. 3️⃣ Cost-effectiveness thresholds ◾ There has been considerable amount of research into methodology & CE modelling to increase the quality of models & certainty around the ICER, but not the same amount of research on the thresholds ICERs are assessed against. ◾ The use of sequential assessments means we are comparing assessments with the threshold, rather than with each other - how do these new treatments compare against each other, what should the new treatment displace, & (controversially), could the use of QALY/ICER league tables provide more practical output for health care systems? ◾ Having the ability to apply a modifier to the QALY is important to reflect variation in condition, but should this modification be quantifiable or deliberative? Quantification of severity, although useful, can lead to additional ethical considerations so is a deliberative approach more appropriate? All in all, lots of positive improvements happening in the HTA space, but an acknowledgement of the challenges ahead. We are looking forward to watching things evolve over the next 25 years of NICE!